The GCC Innovative Drug Discovery and Development (IDDD) Consortium invites you to register to audit this short “crash” course that will cover various aspects of therapeutics commercialization career opportunities within this space.  Though cancer will be highlighted, the various aspects of therapeutics commercialization and careers will be largely disease-agnostic, so all are welcome.  Topics to be covered include 1) understanding disease, need, target population, market, and competitive landscape; 2) end game development goals and target produce profile; 3) strategies for when to file invention disclosures and patents and when to license; 4) commercialization strategies; 5) Funding; 6) preclinical/IND-enabling studies; 7) clinical trials; 8) NDA and post approval; and 9) the final day highlighting the Houston therapeutics landscape and small biotech companies.  Career panel discussions will take place in the afternoon of each day.  Confirmed speakers include Sarah Hein (TMCi), Phil Jones (MDA), Wei Wan (TAMU), Larry Hope (MDA), John Shultz (HMRI), Suzanne Tomlinson (GCC), Enrique Gomez (TMCi), and Andrew Strong (Hogan Lovells).  Those who register to audit the course will participate via Zoom.  The course will start at 10 am each day and end by 3 pm.